GANX (Gain Therapeutics) Other Financing: $3.08 Mil (TTM As of Mar. 2026)


GANX Gain Therapeutics Inc GANX
32 GF Score
Price $2.07
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Other Financing?

Gain Therapeutics GANX +1.86% 32 Other Financing is $3.08 Mil as of Mar. 2026. GuruFocus rates GANX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Gain Therapeutics's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Gain Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $3.08 Mil.

Gain Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics Other Financing Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -0.84 0.00 0.00 -0.11 3.07

Gain Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.35 3.43 0.00
GANX
32GF Score
Gain Therapeutics Inc GANX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $3.08 Mil mean?
Gain Therapeutics (GANX) has a Other Financing of $3.08 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Gain Therapeutics and its competitors.
Is Gain Therapeutics' Other Financing too high?
Gain Therapeutics' current Other Financing is $3.08 Mil. Overall, Gain Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' Other Financing compare to HYFT and ELTX?
Gain Therapeutics' Other Financing of $3.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Gain Therapeutics and its competitors. Gain Therapeutics's current Other Financing is $3.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current Other Financing of $3.08 Mil. The current Other Financing is $3.08 Mil. Gain Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current Other Financing is $3.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
32GF Score

Get the complete analysis for GANX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price